Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 1/2 2Phase 2 1

Status

Active not recruiting 12Recruiting 6Completed 5Withdrawn 1Unknown 1Terminated 1

Sponsor Class

INDUSTRY 4OTHER 2

Study Type

Interventional 6

Sponsor

Cancer Type

Breast 6Genitourinary 2Dermatologic 2Tumor-Agnostic 1Sarcoma 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1Gynecologic 1CNS 1

Conditions

Breast Neoplasms 5Neoplasm Metastasis 1Melanoma 1Locally Advanced (Inoperable) or Metastatic Breast Cancer 1Disease Progression 1

Interventions

pembrolizumab 78Fulvestrant 76Carboplatin 74Trastuzumab 71Capecitabine 70Letrozole 63Cyclophosphamide 61Paclitaxel 60Specimen Handling 54pertuzumab 52Docetaxel 50abemaciclib 46ribociclib 45Anastrozole 36Magnetic Resonance Spectroscopy 35130-nm albumin-bound paclitaxel 35trastuzumab deruxtecan 34Blood Specimen Collection 33exemestane 32Tamoxifen 32Biopsy 32sacituzumab govitecan 31Gemcitabine 30Epirubicin 29pyrotinib 28palbociclib 28Drug Therapy 28Surveys and Questionnaires 27Injections 27eribulin 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Recruiting × capivasertib × Breast × Clear all
NCT04862663 2026-05-27

CAPItello-292

AstraZeneca

Phase 3 Recruiting
895 enrolled
Breast

Locally Advanced (Inoperable) or Metastatic Breast Cancer

NCT07287917 2026-05-12

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

Aminex Therapeutics, Inc.

Phase 1/2 Recruiting
92 enrolled
BreastDermatologic

Breast Neoplasms, Melanoma

NCT06982521 2026-05-08

ReDiscover-2

Relay Therapeutics, Inc.

Phase 3 Recruiting
540 enrolled
Breast

Breast Neoplasms

NCT07281833 2026-02-27

CAPIcorn

West German Study Group

Phase 3 Recruiting
250 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis, Disease Progression

NCT05563220 2026-01-06

ELEVATE

Stemline Therapeutics, Inc.

Phase 1/2 Recruiting
435 enrolled
Breast

Breast Neoplasms

NCT05720260 2024-06-10

Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC

National Taiwan University Hospital

Phase 2 Recruiting
42 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡